&nbsp;

Jan 2025

Drug

raltitrexed

Other Name(s): Tomudex®

Quick Link(s):

Sep 2024

Drug

riTUXimab

Other Name(s): Rituxan® , Truxima™ , Riximyo™ , Ruxience™ , Riabni™

Quick Link(s):

Jun 2025

Drug

pegylated liposomal DOXOrubicin

Other Name(s): Caelyx®

Quick Link(s):

Sep 2025

Drug

PERTuzumab

Other Name(s): Perjeta®

Quick Link(s):

Sep 2022

Drug

romidepsin

Other Name(s): Istodax®

Quick Link(s):

Mar 2023

Drug

ramucirumab

Other Name(s): Cyramza®

Quick Link(s):

Mar 2023

Drug

pembrolizumab

Other Name(s): Keytruda®

Quick Link(s):

Sep 2025

Regimen

PGLDX

Cancer Type:

Gynecologic,

Ovary

Intent: Palliative

Funding:

New Drug Funding Program

Liposomal DOXOrubicin - Single Agent Treatment of Platinum Sensitive Ovarian Fallopian Tube or Primary Peritoneal Cancer

New Drug Funding Program

Liposomal Doxorubicin - Platinum-Resistant Ovarian Fallopian Tube or Primary Peritoneal Cancer

pegylated liposomal DOXOrubicin

Drugs Used:

Quick Link(s):

Regimen Monograph

Mar 2025

Regimen

PGLDX

Cancer Type:

Sarcoma,

Kaposi's Sarcoma

Intent: Palliative

Funding:

New Drug Funding Program

Liposomal Doxorubicin - HIV-positive Kaposi's Sarcoma

pegylated liposomal DOXOrubicin

Drugs Used:

Quick Link(s):

Regimen Monograph

Mar 2025

Regimen

PNTM

Cancer Type:

Gastrointestinal,

Colorectal,

Small bowel and appendix

Intent: Palliative

Funding:

New Drug Funding Program

Panitumumab - Metastatic Colorectal Small Bowel or Appendiceal Cancer

Drugs Used:

PANitumumab

Quick Link(s):

Regimen Monograph

Aug 2023

Regimen

PACL(W); PACL(W)+TRAS

Cancer Type:

Breast

Intent: Palliative

Funding:

New Drug Funding Program

Trastuzumab (Biosimilar) in combination with Chemotherapy - Metastatic Breast Cancer

New Drug Funding Program

Trastuzumab (Biosimilar) - Second Line - Metastatic Breast Cancer

Drugs Used:

PACLitaxel,

trastuzumab